Immunoscape Collaboration & License Agreement was Cue Biopharma’s largest revenue line in fiscal 2025, bringing in $18.90M of $27.40M (69%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Immunoscape Collaboration & License Agreement | — | $18.90M | ||||
| Bi Collaboration & License Agreement | — | $8.10M | ||||
| Collaboration & Option Agreement With Ono | $9.20M | $400.00K | ||||
| Collaboration Agreement With Lg Chem Life Sciences | $100.00K | — | ||||
| Collaboration Agreement With Merck | — | — | ||||
| Total | $9.30M | $27.40M |
Cue Biopharma brought in $27.40M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. Cue Biopharma regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $9.30M. Immunoscape Collaboration & License Agreement was the largest at $18.90M (69.0%), ahead of Bi Collaboration & License Agreement at $8.10M (29.6%) and Collaboration & Option Agreement With Ono at $400.00K (1.5%).
Cue Biopharma began breaking out Immunoscape Collaboration & License Agreement in fiscal 2025 and Bi Collaboration & License Agreement in fiscal 2025. Cue Biopharma stopped reporting Collaboration Agreement With Lg Chem Life Sciences as a separate revenue line after fiscal 2024, when it brought in $100.00K.
Lg Chem Life Sciences was Cue Biopharma’s largest revenue line in fiscal 2021, bringing in $12.79M of $14.94M (86%).
| Counterparty Name | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|
| Lg Chem Life Sciences | — | $2.58M | $2.98M | $12.79M |
| Merck | $1.14M | $874.00K | $177.00K | $2.16M |
| Total | $1.14M | $3.46M | $3.16M | $14.94M |
Cue Biopharma brought in $14.94M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. That was up 373.6% from $3.16M in fiscal 2020. Lg Chem Life Sciences was the largest at $12.79M (85.6%), ahead of Merck at $2.16M (14.4%).
Compared with fiscal 2020, Merck grew 1,117.5% to $2.16M and Lg Chem Life Sciences grew 329.3% to $12.79M.
Cue Biopharma began breaking out Lg Chem Life Sciences in fiscal 2019, when it brought in $2.58M.
Cue Biopharma (CUE) reports its revenue by collaborative arrangement and arrangement other than collaborative and by counterparty name. In fiscal 2025, Immunoscape Collaboration & License Agreement was its largest revenue line, bringing in $18.90M (69.0% of the total), followed by Bi Collaboration & License Agreement at $8.10M (29.6%).
Immunoscape Collaboration & License Agreement was Cue Biopharma's largest revenue line in fiscal 2025, bringing in $18.90M, or 69.0% of the $27.40M total across its three revenue lines.
Merck grew faster than Lg Chem Life Sciences in fiscal 2021, up 1,117.5% from $177.00K to $2.16M. Lg Chem Life Sciences grew 329.3% to $12.79M.
Every figure comes from Cue Biopharma's annual financial filings, as reported. Each line keeps the name Cue Biopharma gives it, and years follow its fiscal calendar.
Cue Biopharma's revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.